Adelle McGourty

March 18, 2021

DS Biopharma and Nuvothera Enter Option and License Agreement for EPADILIN®

• Nuvothera acquires option to licence rights to develop and commercialise DS Biopharma’s EPADILIN® in the US • DS Biopharma becomes an investor in Nuvothera and […]
January 19, 2021

DS BIOPHARMA ABSTRACTS ACCEPTED AT THE ATOPIC DERMATITIS CENTRE OF REFERENCE AND EXCELLENCE (ADCARE) 2021 CONFERENCE

DS Biopharma (DS) has successfully submitted two abstracts to the Atopic Dermatitis Centre of Reference and Excellence (ADCARE) 2021 conference. A link to the abstract “Steroid-sparing […]
March 6, 2019

Clinical Study Shows Topical DS107 Prevents Disease Exacerbation in Atopic Dermatitis Patients

Dublin, Ireland, March 06 2019 – DS Biopharma (DS) today announced positive results from a new study where continued treatment with 5% DS107 cream not only […]
November 19, 2018

DS Biopharma announces DS107 patent grant in the US for the treatment of atopic dermatitis

Dublin, Ireland, November 19th 2018 – DS Biopharma (DS), a privately held clinical stage biopharmaceutical company specialising in the development of novel bioactive lipids, today announced […]
October 3, 2018

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis

DS Biopharma announces positive top-line phase 2b trial results for DS107 as a topical treatment for mild to moderate atopic dermatitis Dublin, Ireland, October 3rd 2018 […]